Skip to main content

Advertisement

SpringerLink
Log in

Esorubicin (deoxydoxorubicin) has low grade activity in malignant melanoma

Results of an Eastern Cooperative Oncology Group study (EST 2685)

  • Phase II Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

In this phase II trial, twenty patients with advanced, measurable melanoma from ECOG institutions were treated with esorubicin 30 mg/m2 iv every three weeks. Doses were escalated or reduced based on nadir counts. The dose limiting toxicity was leukopenia with no significant thrombocytopenia or anemia. Other toxicities were mild. One patient had skin necrosis with extravasation. Two patients with soft tissue disease had partial remissions and were treated with 9 and 17 courses. One patient was stable for 8 courses. No cardiac toxicity was seen in three patients receiving more than 150 mg/m2. The response rate was 10% (90% CI = 2 to 30%). Low level activity was seen, but it is unlikely that this drug has sufficient activity to warrant further development in melanoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Arcamone F: Adriamycin and its analogs. Tumori 70 (2): 113–119, 1984

    Google Scholar 

  2. Bellini O, Savi G, Casazza M: Investigations on the antitumor and cardiotoxicity of anthracyclines in C3H mice. Proc 12th Int Congress of Chemotherapy, Florence, Italy, p 301, 1981

  3. Salmon SE, Young L, Soehnlen B, Liu R: Antitumor activity of esorubicin in human clonogenic assay with comparisons to doxorubicin. J Clin Onc 2 (4): 282–286, 1984

    Google Scholar 

  4. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Onc 5: 649–655, 1982

    CAS  PubMed  Google Scholar 

  5. Villani F, Comazzi R, Genitoni V, Lacaita G, Guidani A, Crippa F, Monti E, Piccinini F, Rozza A, Lanza E: Preliminary evaluation of myocardial toxicity of 4′ deoxydoxorubicin experimental and clinical results. Drugs Exp Clin Res 11:223–231, 1985

    Google Scholar 

  6. Blayney D: Cardiotoxicity associated with 4′ deoxydoxorubicin. Cancer Treat Rep 70: 433, 1986

    Google Scholar 

  7. Dich LF, Banks T, Carter W, Klein MA, Miss HB, Weiss RB: Fatal doxorubicin induced cardiomyopathy. Cancer Chemother Pharmacol 21: 347–350, 1988

    Google Scholar 

  8. Carlson RW, Williams RB, Billingham ME, Kohler M, Torti FM: Phase II trial of esorubicin in the treatment of metastatic carcinoma of the kidney. Cancer Treat Rep 71: 767–768, 1987

    Google Scholar 

  9. Carlson RW, Billingham M, Kohler M, Johnson FD, Doroshow JH, Torti FM: Esorubicin in refractory metastatic carcinoma of the breast: A NCOG study. Cancer Treat Rep 71: 427–428, 1987

    Google Scholar 

  10. Bonfante V, Ferrari L, Brambilla C, Rossi A, Villani F, Crippa F, Valagussa P, Bonadonna G: New anthracycline analogs in advanced breast cancer. Eur J Cancer Clin Onc 22: 1379–1385, 1986

    Google Scholar 

  11. Braich TA, Salmon SE, Robertone A, Alberts DS, Jones SE, Miller TP, Garewal HS: Phase II trial of esorubicin in cancers of the breast, colon, kidney, lung and melanoma. Invest New Drugs 4: 269–274, 1986

    Google Scholar 

  12. Falkson G, Vorbiof DA: Phase II study of 4′ deoxydoxorubicin in advanced colorectal cancer. Invest New Drugs 4: 165–169, 1986

    Google Scholar 

  13. Frustaci S, Gasparini G, Galligioni E, Tirelli U, DiPietro N, Crivellari D, LoRe G, Monfardini S: Phase II trial of esorubicin in patients with advanced melanoma. Cancer Treat Rep 71: 325–326, 1987

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. New York University Medical Center, 16395, New York, CA, USA

    Howard Hochster & Michael Green

  2. Dana-Farber Cancer Institute, Harvard School of Public Health, (CA 23318), Boston, MA

    Myla Hunt

  3. New York University Medical Center, 530 First Avenue, 10016, New York, NY, USA

    David Parkinson & Thomas Smith

Authors
  1. Howard Hochster
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Myla Hunt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Green
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David Parkinson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Thomas Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Other participating institutions include: Albany Medical College, Albany, NY (CA 06594); Charleston Area Medical Center, Charleston, WV; Fox Chase Cancer Center, Philadelphia, PA (CA 18281); Indiana University Medical Center, Indianapolis, IN; Medical College of Ohio, Toledo, OH; University of Minnesota, Minneapolis, MN (CA 20365); Rush-Presbyterian-St.Luke's Medical Center, Chicago, IL (CA 25988); University of Pretoria, Pretoria, South Africa (CA 21692); Natalie Warren Bryant Cancer Center, Tulsa, OK; University of Wisconsin Clinical Cancer Center, Madison, WI (CA 21076); West Virginia University, Morgantown, WV.

Dr. Hochster is a recipient of an American Cancer Society Cancer Development Award and is supported in part by the Kaplan Cancer Center grant CA 16087.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hochster, H., Hunt, M., Green, M. et al. Esorubicin (deoxydoxorubicin) has low grade activity in malignant melanoma. Invest New Drugs 8, 329–332 (1990). https://doi.org/10.1007/BF00171849

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00171849

Key words

Search

Navigation